Associate Professor, Schools of Pharmacy, University of Reading
I have been working on neurodegenerative diseases for over ten years, first at the Mayo Clinic in Florida where I worked on the molecular basis of Alzheimer’s disease. I then carried out graduate studies at the Medical Research Council Prion Unit at the UCL Institute of Neurology where I completed a PhD on the molecular characteristics of the Scrapie agent in 2005. I started working on Parkinson’s disease at the National Institute on Aging in Bethesda in the Laboratory of Neurogenetics under Mark Cookson. It was in Bethesda that I first came across Leucine Rich Repeat Kinase 2, LRRK2, a protein which I have been investigating ever since. In 2007 I returned to the UCL Institute of Neurology and the Department of Molecular Neuroscience.